Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes

Diabetes Therapy

Volumn 5, Issue 1, 2014, Pages 323-332

  Kishimoto, Miyako ^a   Noda, Mitsuhiko ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Exenatide; Glucagon; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Insulin sensitivity; Type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CASE REPORT; DRUG EFFECT; FEMALE; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOSS OF APPETITE; MIDDLE AGED; MORBIDITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 84926027253     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-014-0050-6     Document Type: Article

References (50)

1. World Health Organization. Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 13 January 2014).
2. Goto M, Morita A, Goto A, SCOP Study Group, et al. Reduction in adiposity, β-cell function, insulin sensitivity, and cardiovascular risk factors: a prospective study among Japanese with obesity. PLoS ONE. 2013;8:e57964.
3. Wing RR, Lang W, Wadden TA, Look AHEAD Research Group, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.
4. Matsushita Y, Nakagawa T, Yamamoto S, et al. Effect of longitudinal changes in visceral fat area and other anthropometric indices to the changes in metabolic risk factors in Japanese men: the Hitachi Health Study. Diabetes Care. 2012;35:1139–43.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
6. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.
7. Harayama T, Yoshida T, Yoshioka K, et al. Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients. Diabetol Int. 2013;4:132–7.
8. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65.
9. Drucker DJ. Incretin-based therapy and the quest for sustained improvements in β-cell health. Diabetes Care. 2011;34:2133–5.
10. Holst JJ, Deacon CF. Is there a place for incretin therapies in obesity and prediabetes? Trends Endocrinol Metab. 2013;24:145–52.
11. Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215–21.
12. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol. 2010;92:442–62.
13. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol. 2009;70:343–53.
14. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003;88:2706–13.
15. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33:1173–5.
16. Unger JR, Parkin CG. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabetes Ther. 2011;2:29–39.
17. Buse JB, Rosenstock J, Sesti G, LEAD-6 Study Group, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
18. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419–28.
19. Mathieu C, Ostenson CG, Matthaei S, et al. Using exenatide twice daily or insulin in clinical practice: results from CHOICE. Diabetes Ther. 2013;4:285–308.
20. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8:436–47.
21. Al-Jebawi AF. Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment. Diabetes Res Clin Pract. 2010;90:e88–90.
22. Buysschaert M, Preumont V, Oriot PR, UCL Study Group for Exenatide, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36:381–8.
23. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition. 2010;26:243–9.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.
25. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–95.
26. Quon MJ. QUICKI is a useful and accurate index of insulin sensitivity. J Clin Endocrinol Metab. 2002;87:949–51.
27. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
28. Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Holst JJ, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety–effect of obesity and weight reduction. Int J Obes Relat Metab Disord. 2001;25:1206–14.
29. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2008;57:1340–8.
30. Ghazi T, Rink L, Sherr JL, Herold KC. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and IV glucose challenges. Diabetes Care. 2014;37:210–6.
31. Gumbiner B, Polonsky KS, Beltz WF, et al. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab. 1990;70:1594–602.
32. Villareal DT, Banks MR, Patterson BW, Polonsky KS, Klein S. Weight loss therapy improves pancreatic endocrine function in obese older adults. Obesity. 2008;16:1349–54.
33. Prentki M, Nolan CJ. Islet β cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802–12.
34. Parnaud G, Bosco D, Berney T, et al. Proliferation of sorted human and rat beta cells. Diabetologia. 2008;51:91–100.
35. Perl S, Kushner JA, Buchholz BA, et al. Significant human beta-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating. J Clin Endocrinol Metab. 2010;95:E234–9.
36. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8.
37. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–70.
38. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269:540–3.
39. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543–6.
40. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546–9.
41. Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron. 2003;37:649–61.
42. Bunck MC, Diamant M, Cornér A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32:762–8.
43. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
44. Ottney A. Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. Am J Health Syst Pharm. 2013;70:2097–103.
45. Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163–72.
46. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15:42–54.
47. Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97:258–66.
48. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443–51.
49. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234–43.
50. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35:683–9.